Arrayit Corporation Receives Registered Trademark for OvaDx(R) - financial news

"Arrayit's OvaDx(R), the market's first comprehensive diagnostic screening test for ovarian cancer, uses approximately 100 proteomic biomarkers to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as soon as an ovarian tumor begins to develop. OvaDx(R) detects both early and late stage ovarian cancer with high sensitivity and specificity using Arrayit's proprietary microarrays, which are tiny medical devices that screen large numbers of patient samples in a highly miniaturized and automated manner. OvaDx(R) leverages Arrayit's patented manufacturing technology and will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc."

Arrayit Corporation Reports Strong Surge in Customer Demand for the Company's Leading Edge Life Sciences Microarray Instruments - financial news

Note: in prior new/press releases the Arrayit testing is still seeking FDA (U.S.) approval, this is not the same test as OVA1 which is the test for determining suspicion of ovarian cancer malignancy (search blog for further information on both)

"Arrayit microarrays and instruments offer richer content and greater sensitivity than competing platforms, and these attributes have allowed us to discover the world's only definitive pre-symptomatic biomarkers for ovarian cancer and Parkinson's Disease, as well as a new pharmaceutically important pathway in human biology that will be the subject of future announcements."